{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreidlydp2bv7eylyjw5l6zuo3vczcc7z54bfxckzzuay66pfo5ekqvy",
    "uri": "at://did:plc:pmmp7irwts7faw56jdxk3idc/app.bsky.feed.post/3mo24pagfdq62"
  },
  "coverImage": {
    "$type": "blob",
    "ref": {
      "$link": "bafkreian77grl6ssqmav7n246qn72b2iuoiumcosvzpxhmchsw5bx4ggnu"
    },
    "mimeType": "image/jpeg",
    "size": 279002
  },
  "path": "/news/2026-06-antibody-boost-kras-lung-cancer.html",
  "publishedAt": "2026-06-11T15:20:01.000Z",
  "site": "https://medicalxpress.com",
  "textContent": "An experimental antibody treatment that binds to a protein known as PCDH7 shrank tumors in preclinical models of non-small cell lung cancer (NSCLC), including those resistant to a targeted therapy, a study led by UT Southwestern Medical Center researchers showed. The findings, published in Science Advances, could eventually lead to a new class of drugs to treat NSCLC and potentially other cancers.",
  "title": "New antibody may boost KRAS-targeted lung cancer treatment after resistance emerges"
}